Zydus Lifesciences Share Price Falls Over 2% After Q2 FY27 Earnings Results: Total Income Up 29% YoY

On November 4, 2026, Zydus Lifesciences Limited released its consolidated unaudited financial results for the quarter and half‑year ended September 30, 2026, showing mixed performance across revenue and profit metrics, as per the exchange filings. 

Zydus Lifesciences Q2 FY27 Earnings Results 

Zydus Lifesciences Limited's total income up 29.0% YoY to ₹8,039.50 crore in the September 2026 quarter from ₹6,232.20 crore a year ago, but down 1.0% QoQ from ₹8,123.10 crore in the June 2026 quarter. 

Net profit (PAT) down 26.6% YoY to ₹925.50 crore in the September 2026 quarter from ₹1,260.90 crore a year ago, and down 3.6% QoQ from ₹960.40 crore in the June 2026 quarter. 

Half‑Year Financial Summary  

For the six months ended September 30, 2026, total income was ₹15,926.60 crore, up 22.9 % YoY from ₹12,960.80 crore. Net profit (PAT) for the half year fell to ₹1,885.90 crore, down 30.9 % YoY from ₹2,727.70 crore. 

FY26 Financial Performance 

For FY26, total income stood at ₹27,657.90 crore and net profit (PAT) stood at ₹5,094.70 crore. 

Segment Wise Revenue Breakdown for the Quarter 

Consolidated revenue from operations for the quarter stood at ₹7,909.60 crore. Pharmaceutical revenue contributed ₹6,558.20 crore, consumer products ₹1,125.70 crore and medical technologies ₹225.70 crore. Total assets were reported at ₹55,606.90 crore. 

Read More: Garden Reach Shipbuilders & Engineers Share Price Gains 6%; Board Meet Rescheduled! 

Key Corporate Developments and Settlement Payments 

Zydus Worldwide DMCC settled litigation with Teva Parties, receiving ₹146.80 crore (≈ USD 15.5 million) related to supply obligations under an Asset Purchase Agreement.  

The company also agreed to pay USD 120 million to Astellas Pharma, comprising USD 45 million for one‑time settlement costs and USD 75 million for licensing fees. 

Zydus Lifesciences Share Price Performance 

As of November 04, 2026, at 12:37 PM, Zydus Lifesciences share price on NSE was trading at ₹1,204.20, down by 2.93% from the previous closing price. 

Conclusion 

Zydus Lifesciences September 2026 quarter showed strong revenue growth but a decline in profit, while the half‑year results reflected higher income and lower profit compared with the prior year. Segment contributions remained led by pharmaceuticals, and corporate settlements amounted to significant cash inflows and outflows. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.